Home > PE Ratio > NATCO PHARMA

NATCO PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of NATCO PHARMA is 14.01.

Share Price ₹999.5Apr 24,2024
Market Cap ₹17,900.1 Cr
Earnings-TTM₹1,277.8 CrTTM-Consolidated Results
Price/Earnings14.01xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results
NATCO PHARMA is part of below Screeners ↓
Top Undervalued Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of NATCO PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of NATCO PHARMA is calculated as :

Current Market Cap [ ₹17,900.1 Cr] as on Apr 24,2024

(/) Earnings [ ₹1,277.8 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 14.01x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for NATCO PHARMA , the investors are currently willing to pay 14.01 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NATCO PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of NATCO PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of NATCO PHARMA


PE Ratio Performance Analysis for NATCO PHARMA

- NATCO PHARMA 's latest p/e ratio is 14.01x.

- NATCO PHARMA 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 33.20x.

- NATCO PHARMA 's operated at median p/e ratio of 19.99x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, NATCO PHARMA 's p/e ratio peaked in Mar2022 at 81.3x.

- NATCO PHARMA 's p/e ratio hit its five-year low in Mar2023 of 14.38x.


How does NATCO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
NATCO PHARMA 1,277.8014.0117,900.1
SUN PHARMACEUTICAL INDUSTRIES LTD8,998.6339.63356,625.0
CIPLA LTD3,744.0330.16112,938.0
DR REDDYS LABORATORIES LTD5,209.4019.0699,276.9
ZYDUS LIFESCIENCES LTD2,954.2031.7993,921.9
DIVIS LABORATORIES LTD1,382.9773.26101,315.0
MANKIND PHARMA LTD1,743.3055.1596,143.2
TORRENT PHARMACEUTICALS LTD1,494.0060.8390,872.6
LUPIN LTD1,809.7439.7972,010.8
AUROBINDO PHARMA LTD2,777.8922.8663,492.3
ABBOTT INDIA LTD1,145.5847.2354,105.4

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NATCO PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 14.01x
Max industry PE 73.26x
Median industry PE 39.63x
Average industry PE 39.43x



You may also like the below Video Courses